Other languages Larimar Therapeutics, Inc.

Equities

LRMR

US5171251003

Real-time Estimate Cboe BZX Other stock markets 13:41:24 2024-05-09 EDT			5-day change	1st Jan Change
7.84 ^USD	-1.01%		+2.69%	+71.76%

01:02pm	Larimar Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
01:00pm	Zafgen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Larimar Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07:02am
Zafgen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07:00am
Larimar Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-14
Larimar Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-14
Sector Update: Health Care Stocks Gain Premarket Tuesday	03-12
Larimar Therapeutics Doses 1st Patient in Study of Movement Disorder Treatment	03-11
Larimar Therapeutics Announces the Dosing of the First Patient in Long-Term Open Label Extension Study for Nomlabofusp in Patients with Friedreich?S Ataxia	03-11
Top Midday Gainers	02-14
Larimar Therapeutics Starts Public Offering of Common Shares, Pre-Funded Warrants	02-14
Top Midday Gainers	02-13
Larimar Therapeutics Says Potential Friedreich's Ataxia Drug Well-Tolerated in Phase 2 Study	02-12
Larimar Therapeutics, Inc. Reports Positive Top-Line Data from Phase 2 Dose Exploration Study from 25 Mg and 50 Mg Cohorts of Nomlabofusp in Patients with Friedreich's Ataxia	02-12
Larimar Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14
Larimar Therapeutics, Inc. Appoints Dr. Jeffery W. Sherman to its Board of Directors	23-10-03
Larimar Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10
Larimar Therapeutics Gets FDA Clearance to Proceed With Trials; Shares Rise	23-07-25
Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601's Phase 2 Friedreich's Ataxia Trial	23-07-25
Larimar Therapeutics, Inc. Announces Chief Medical Officer Changes	23-07-17
Larimar Therapeutics Poised to Join Russell 3000 Index	23-06-22
Larimar Therapeutics Phase 2 Dose Exploration Study Shows CTI-1601 'Generally Well Tolerated' in Friedreich's Ataxia Trial	23-05-15

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Larimar Therapeutics, Inc.

Equities

LRMR

US5171251003

Other languages

Filters